Skip to main content

Table 1 Clinical Characteristics of CHD Patients and Healthy controls

From: TRIB1 rs17321515 gene polymorphism increases the risk of coronary heart disease in general population and non-alcoholic fatty liver disease patients in Chinese Han population

Parameters CHD (n = 155) Controls (n = 175) Statistics P value
Male/Female 83/72 88/87 χ2 = 0.350 0.554
Age, y 60.00 (59.00, 75.00) 62.00 (53.00, 68.00) Z = −1.013 0.311
BMI, kg/m2 24.20 ± 2.73 22.44 ± 2.88 t = 5.632 < 0.001
ALT, U/L 19.21 (14.57, 33.40) 17.96 (12.57, 24.20) Z = −2.239 0.025
AST, U/L 22.45 (16.70, 37.78) 20.78 (17.60, 24.35) Z = −1.924 0.054
GGT, U/L 23.75 (17.09, 36.74) 19.91 (15.24, 29.92) Z = −2.117 0.034
ALP, U/L 83.84 (66.72, 109.08) 69.71 (57.27, 83.63) Z = −1.083 0.279
TG, mmol/L 1.23 (0.90, 1.61) 1.12 (0.86, 1.62) Z = −3.026 0.002
TC, mmol/L 4.19 (3.71, 5.13) 4.64 (3.66, 5.18) Z = −1.525 0.127
HDL, mmol/L 1.00 (0.85, 1.20) 1.31 (1.05, 1.47) Z = −7.493 < 0.001
LDL, mmol/L 2.49 (2.06, 3.18) 3.01 (2.61, 3.56) Z = −3.552 < 0.001
TBIL, μmol/L 13.50 (10.60, 17.96) 12.10 (9.50, 15.10) Z = − 0.366 0.714
FPG, mmol/L 5.02 (4.49, 6.02) 4.54 (4.06, 5.05) Z = −5.879 < 0.001
pharmacological history lipid-lowering drug /   
  1. Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FPG, fasting plasma glucose; GGT, γ-glutamyltransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TBIL, total bilirubin; TC, total cholesterol; TG, triglyceride